Samsung Biologics Co.,Ltd. (207940.KS)
KRW 959000.0
(-2.14%)
KRW 959000.0
(-2.14%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3694.58 Billion KRW | 23.1% |
| 2022 | 3001.29 Billion KRW | 91.41% |
| 2021 | 1568 Billion KRW | 34.62% |
| 2020 | 1164.77 Billion KRW | 66.02% |
| 2019 | 701.59 Billion KRW | 30.94% |
| 2018 | 535.8 Billion KRW | 15.32% |
| 2017 | 464.62 Billion KRW | 57.7% |
| 2016 | 294.62 Billion KRW | 222.77% |
| 2015 | 91.27 Billion KRW | -13.19% |
| 2014 | 105.14 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1156.9 Billion KRW | 22.18% |
| 2024 Q3 | 1187.07 Billion KRW | 2.61% |
| 2024 Q1 | 946.9 Billion KRW | -11.79% |
| 2023 Q1 | 720.92 Billion KRW | -25.33% |
| 2023 Q3 | 1033.97 Billion KRW | 19.37% |
| 2023 Q2 | 866.18 Billion KRW | 20.15% |
| 2023 Q4 | 1073.5 Billion KRW | 3.82% |
| 2023 FY | 3694.58 Billion KRW | 23.1% |
| 2022 Q2 | 651.42 Billion KRW | 27.4% |
| 2022 FY | 3001.29 Billion KRW | 91.41% |
| 2022 Q4 | 965.52 Billion KRW | 10.59% |
| 2022 Q3 | 873.04 Billion KRW | 34.02% |
| 2022 Q1 | 511.3 Billion KRW | 15.08% |
| 2021 Q2 | 412.16 Billion KRW | 58.04% |
| 2021 FY | 1568 Billion KRW | 34.62% |
| 2021 Q4 | 444.31 Billion KRW | -1.42% |
| 2021 Q3 | 450.73 Billion KRW | 9.36% |
| 2021 Q1 | 260.79 Billion KRW | -30.51% |
| 2020 Q4 | 375.3 Billion KRW | 36.68% |
| 2020 Q3 | 274.58 Billion KRW | -10.76% |
| 2020 Q1 | 207.19 Billion KRW | -33.87% |
| 2020 FY | 1164.77 Billion KRW | 66.02% |
| 2020 Q2 | 307.69 Billion KRW | 48.5% |
| 2019 Q1 | 125.36 Billion KRW | -29.68% |
| 2019 FY | 701.59 Billion KRW | 30.94% |
| 2019 Q4 | 313.32 Billion KRW | 69.53% |
| 2019 Q3 | 184.81 Billion KRW | 136.7% |
| 2019 Q2 | 78.08 Billion KRW | -37.72% |
| 2018 Q2 | 125.42 Billion KRW | -4.28% |
| 2018 FY | 535.8 Billion KRW | 15.32% |
| 2018 Q4 | 178.27 Billion KRW | 76.39% |
| 2018 Q3 | 101.06 Billion KRW | -19.42% |
| 2018 Q1 | 131.03 Billion KRW | -21.21% |
| 2017 Q4 | 166.31 Billion KRW | 30.49% |
| 2017 Q1 | 107.64 Billion KRW | 1.99% |
| 2017 FY | 464.62 Billion KRW | 57.7% |
| 2017 Q2 | 63.21 Billion KRW | -41.27% |
| 2017 Q3 | 127.45 Billion KRW | 101.61% |
| 2016 Q3 | 52.78 Billion KRW | 11.04% |
| 2016 Q2 | 47.53 Billion KRW | -46.44% |
| 2016 Q4 | 105.55 Billion KRW | 99.97% |
| 2016 Q1 | 88.75 Billion KRW | 0.0% |
| 2016 FY | 294.62 Billion KRW | 222.77% |
| 2015 FY | 91.27 Billion KRW | -13.19% |
| 2014 FY | 105.14 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ORIENT BIO Inc. | 28 Billion KRW | -13092.544% |
| Green Cross Holdings Corporation | 2057.93 Billion KRW | -79.529% |
| Green Cross Holdings Corporation | 1626.64 Billion KRW | -127.13% |
| Pharmicell Co., Ltd. | 56.22 Billion KRW | -6470.8% |
| Green Cross Corporation | 1626.64 Billion KRW | -127.13% |
| GeneOne Life Science, Inc. | 40.2 Billion KRW | -9089.854% |
| Celltrion, Inc. | 2176.43 Billion KRW | -69.754% |
| SK bioscience Co.,Ltd. | 369.5 Billion KRW | -899.874% |
| SK Biopharmaceuticals Co., Ltd. | 354.89 Billion KRW | -941.047% |
| Prestige BioPharma Limited | 689.07 Million KRW | -536066.421% |